At 20.1% CAGR, the Asia Pacific Direct-to-Consumer Genetic Testing Market is Projected to be Worth US$ 1,530.84 million by 2030, Says Business Market Insights

According to Business Market Insights' research, the Asia Pacific direct-to-consumer genetic testing market was valued at US$ 354.24 in 2022 and is expected to reach US$ 1,530.84 million by 2030, registering a CAGR of 20.1% from 2022 to 2030. Increasing awareness about potential benefits of genetic testing and growing adoption of Single Nucleotide polymorphism (SNP) chips are among the critical factors attributed to the Asia Pacific direct-to-consumer genetic testing market expansion.

Consumers are increasingly driven by self-curiosity and empowerment, reflected by increased awareness of services that offer genetic testing and follow-up counseling. Awareness and acceptance of genetic testing is steadily increasing among the population worldwide. The shift from passive to empowered and self-aware customers is driving the genetic testing market. The inherent accessibility of direct-to-consumer genetic testing (DTC-GT) is a major advantage, giving consumers free access to their genetic information and personalized insights and recommendations. Many industries are seeing a significant increase in customers seeking tailored products and experiences, with an increased willingness to pay to identify and meet individual needs. Direct-to-consumer genetic testing plays an important role in addressing the increasing burden of various diseases, such as diabetes and certain cancers, by eliminating the need for unnecessary examinations and screening tests and pointing the person to the best available options for prevention, treatment, and monitoring of the condition. The role of genetic testing in all areas of medicine is rapidly increasing. Genetic testing is already speeding up diagnoses, and it aids in identifying people with a genetic predisposition to highly resilient diseases. Preconception and prenatal genetic testing assist potential patients with reproductive decisions by informing them of their carrier status for genetic disorders. The increasing awareness of the importance of genetic variations across a wide range of phenotypes associated with different diseases is further expected to promote market growth. These tests reveal whether a person has a genetic predisposition to a particular disease or phenotype of concern, which can be diagnosed as early as possible to initiate the disease treatment. The first sequencing of the human genome and advances in genome sequencing technology have enabled rapid growth in genomics research. This has also led to direct-to-consumer genetic testing becoming a new service. Direct-to-consumer genetic testing has influenced many people as these tests provide valid information about various health risks, personal characteristics, and overall well-being. Further, the rapid transition of the clinical laboratory workforce to DTC-GT is another crucial factor driving the market. Thus, the growing awareness among the population regarding genetic testing drives the Asia Pacific direct-to-consumer genetic testing market.

On the contrary, high cost and privacy concerns associated with direct-to-consumer genetic testing hamper the growth Asia Pacific direct-to-consumer genetic testing market .

Based on test type, the Asia Pacific direct-to-consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing segment held 64.3% share of the Asia Pacific direct-to-consumer genetic testing market in 2022, amassing US$ 227.74 million. It is projected to garner US$ 954.18 million by 2030 to expand at 19.6% CAGR during 2022-2030.

By technology, the Asia Pacific direct-to-consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held 68.6% share of Asia Pacific direct-to-consumer genetic testing market in 2022, amassing US$ 243.18 million. It is projected to garner US$ 1,079.06 million by 2030 to expand at 20.5% CAGR during 2022-2030.

Based on distribution channel, the Asia Pacific direct-to-consumer genetic testing market is bifurcated into online and offline. The online segment held 65.7% share of Asia Pacific direct-to-consumer genetic testing market in 2022, amassing US$ 232.64 million. It is projected to garner US$ 1,018.14 million by 2030 to expand at 20.3% CAGR during 2022-2030.

Based on country, the Asia Pacific direct-to-consumer genetic testing market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 27.4% share of Asia Pacific direct-to-consumer genetic testing market in 2022, amassing US$ 97.00 million. It is projected to garner US$ 432.79 million by 2030 to expand at 20.6% CAGR during 2022-2030.

Key players operating in the Asia Pacific direct-to-consumer genetic testing market are Genesis Healthcare Co, Ancestry Genomics Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, and Genetic Technologies Ltd, among others.

- In September 2023; 23andMe Holding Co. and the Sickle Cell 101, have joined forces to expand awareness of people's sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe's Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com